

# Vasopressor Choice and Timing in Vasodilatory Shock

Critical Care

26, 76

DOI: [10.1186/s13054-022-03911-7](https://doi.org/10.1186/s13054-022-03911-7)

Citation Report

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | When to start vasopressin in septic shock: the strategy we propose. <i>Critical Care</i> , 2022, 26, 125.  | 5.8 | 10        |
| 2  | Future Perspectives in the Diagnosis and Treatment of Sepsis and Septic Shock. <i>Medicina (Lithuania)</i> , 2022, 58, 844.  | 2.0 | 4         |
| 3  | VASOPRESSOR-RESISTANT HYPOTENSION, COMBINATION VASOPRESSOR THERAPY, AND SHOCK PHENOTYPES IN CRITICALLY ILL ADULTS WITH VASODILATORY SHOCK. <i>Shock</i> , 2022, 58, 260-268.                                     | 2.1 | 1         |
| 4  | Norepinephrine exposure and acute kidney injury after cardiac surgery under cardiopulmonary bypass: A post-hoc cardiox trial analysis. <i>Journal of Clinical Anesthesia</i> , 2022, 83, 110972.                 | 1.6 | 3         |
| 5  | Comment on: Treatment strategies for clozapine-induced hypotension: A systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532211116.  | 2.7 | 0         |
| 6  | Low-dose norepinephrine in combination with hypotensive resuscitation may prolong the golden window for uncontrolled hemorrhagic shock in rats. <i>Frontiers in Physiology</i> , 0, 13, .                        | 2.8 | 0         |
| 7  | Efficacy and safety of methylene blue in patients with vasodilatory shock: A systematic review and meta-analysis. <i>Frontiers in Medicine</i> , 0, 9, .   | 2.6 | 11        |
| 8  | Autonomic and circulatory alterations persist despite adequate resuscitation in a 5-day sepsis swine experiment. <i>Scientific Reports</i> , 2022, 12, .   | 3.3 | 3         |
| 9  | Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support. <i>Journal of Intensive Care Medicine</i> , 0, , 088506662211458.  | 2.8 | 3         |
| 10 | Precision fluid and vasoactive drug therapy for critically ill patients. <i>Pharmacotherapy</i> , 2023, 43, 1182-1193.   | 2.6 | 5         |
| 11 | Multimodal strategy to counteract vasodilation in septic shock. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2023, 42, 101193.  | 1.4 | 10        |
| 12 | Circulatory shock in adults in emergency department. <i>Turkish Journal of Emergency Medicine</i> , 2023, .  | 0.9 | 0         |
| 13 | An updated "norepinephrine equivalent" score in intensive care as a marker of shock severity. <i>Critical Care</i> , 2023, 27, .   | 5.8 | 21        |
| 14 | Norepinephrine in cardiac surgery: The love-hate story. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2023, 42, 101210.  | 1.4 | 0         |
| 15 | All intraoperative hypotension is not created equal " A call for an individualized approach. <i>Journal of Clinical Anesthesia</i> , 2023, 87, 111076.   | 1.6 | 4         |
| 16 | Hydroxocobalamin for Vasodilatory Hypotension in Shock: A Systematic Review With Meta-Analysis for Comparison to Methylene Blue. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2023, 37, 1757-1772. | 1.3 | 6         |
| 17 | Not all Shock States Are Created Equal. <i>Anesthesiology Clinics</i> , 2023, 41, 1-25.  | 1.4 | 1         |
| 18 | Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. <i>Critical Care</i> , 2023, 27, .   | 5.8 | 19        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Timing of vasopressin initiation and mortality in patients with septic shock: analysis of the MIMIC-III and MIMIC-IV databases. BMC Infectious Diseases, 2023, 23, .  | 2.9 | 5         |
| 20 | Emerging concepts in the care of patients with cirrhosis and septic shock. World Journal of Hepatology, 0, 15, 497-514.   | 2.0 | 1         |
| 21 | Tris-Hydroxymethyl Aminomethane in Critically Ill Adults: A Systematic Review. Anesthesia and Analgesia, 2023, 137, 1007-1018.  | 2.2 | 1         |
| 22 | Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Critical Care, 2023, 27, .  | 5.8 | 14        |
| 23 | Circulatory shock in adults in emergency department. Turkish Journal of Emergency Medicine, 2023, 23, 139.  | 0.9 | 2         |
| 24 | Intraoperative arterial pressure management: knowns and unknowns. British Journal of Anaesthesia, 2023, 131, 445-451.   | 3.4 | 2         |
| 25 | Early administration of multiple vasopressors is associated with better survival in patients with sepsis: a propensity score-weighted study. European Journal of Medical Research, 2023, 28, .                | 2.2 | 0         |
| 26 | Management of Sepsis and Septic Shock: What Have We Learned in the Last Two Decades?. Microorganisms, 2023, 11, 2231.   | 3.6 | 3         |
| 27 | Management of Vasoplegic Shock in the Cardiovascular Intensive Care Unit after Cardiac Surgery. Critical Care Clinics, 2024, 40, 73-88.   | 2.6 | 1         |
| 28 | Blood Pressure Goals in Critically Ill Patients. Methodist DeBakey Cardiovascular Journal, 2023, 19, 24-37.   | 1.0 | 0         |
| 29 | Vasopressin initiation as a Second-Line Vasopressor in Early Septic Shock (VIS PSS). Journal of Intensive Care Medicine, 2024, 39, 306-312.   | 2.8 | 0         |
| 30 | Comment on "Hydrocortisone versus vasopressin for the management of adult patients with septic shock refractory to norepinephrine: A multicenter retrospective study". Pharmacotherapy, 2023, 43, 1094-1094.  | 2.6 | 0         |
| 31 | Vasopressin in Sepsis and Other Shock States: State of the Art. Journal of Personalized Medicine, 2023, 13, 1548.   | 2.5 | 1         |
| 32 | The never-ending quest to equate vasopressor dosages. Journal of Critical Care, 2023, , 154460.   | 2.2 | 0         |
| 33 | Diffuse extremity vascular malformation in the setting of septic shock and pneumonia "A case report. , 2024, 3, 100236.   |     | 0         |
| 34 | Is It Time to Reconsider the Concept of "Salvage Therapy" in Refractory Shock?*. Critical Care Medicine, 2023, 51, 1821-1824.   | 0.9 | 0         |
| 35 | Severe Refractory Vasoplegic Shock Syndrome after OPCABG Successfully Treated with Hydroxycobalamin: A Case Report and Review of the Literature. Journal of Clinical Medicine, 2024, 13, 169.                 | 2.4 | 0         |
| 36 | Mean arterial pressure to norepinephrine equivalent dose ratio for predicting renal replacement therapy requirement: a retrospective analysis from the MIMIC-IV. International Urology and Nephrology, 0, , . | 1.4 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Position Paper on the Reporting of Norepinephrine Formulations in Critical Care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force. <i>Critical Care Medicine</i> , 2024, 52, 521-530.  | 0.9 | 1         |
| 38 | Clinical Response to Third-Line Angiotensin-II vs Epinephrine in Septic Shock: A Propensity-Matched Cohort Study. <i>Annals of Pharmacotherapy</i> , 0, , .  | 1.9 | 0         |
| 39 | Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review. <i>Journal of Anesthesia, Analgesia and Critical Care</i> , 2024, 4, .  | 1.3 | 0         |
| 41 | Knowing the ropes of vasopressor dosing: a focus on norepinephrine. <i>Intensive Care Medicine</i> , 2024, 50, 587-589.  | 8.2 | 0         |
| 42 | The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock. <i>Trials</i> , 2024, 25, . | 1.6 | 0         |